Given the potential for galectin-3 to serve as a marker of both metabolic dysfunction and inflammation, targeting galectin-3 with inhibitors—alongside optimized metformin therapy—could provide a promising approach for improving clinical outcomes in PCOS, including metabolic and reproductive health. This evidence concerns the gene LGALS3 and polycystic ovary syndrome.